Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

PHASE4CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
HIV Infection
Interventions
DRUG

Darunavir/Ritonavir

Darunavir/ritonavir (800/100 mg): QD (quaque die )

DRUG

Lamivudine

Lamivudine (300mg) : QD

DRUG

Emtricitabine/tenofovir or abacavir/lamivudine

Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD

Trial Locations (21)

Unknown

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat

Hospital General Universitario de Alicante, Alicante

Hospital Universitario Germans Trias i Pujol, Badalona

Hospital Clinic, Barcelona

Hospital de La Santa Creu I Sant Pau, Barcelona

Hospital del Mar, Barcelona

Hospital Universitario Vall D'Hebron, Barcelona

Hospital Universitario Reina Sofía, Córdoba

Hospital Universitario Virgen de las Nieves, Granada

Complejo Hospitalario de Huelva, Huelva

Hospital 12 de Octubre, Madrid

Hospital Universitario Clínico San Carlos, Madrid

Hospital Universitario Fundación Alcorcón, Madrid

Hospital Universitario Gregorio Marañón, Madrid

Hospital universitario Infanta Leonor, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario Príncipe de Asturias, Madrid

Hospital de Mataró, Mataró

Hospital Universitario Virgen de la Victoria, Málaga

Hospital Universitario Donostia, San Sebastián

Hospital Universitario Miguel Servet, Zaragoza

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Fundacion SEIMC-GESIDA

OTHER

NCT02159599 - Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject | Biotech Hunter | Biotech Hunter